Ofev (Nintedanib)

Nintedanib inhibits several receptor tyrosine kinases such as VEGFR, PDGFR and FGFR. By blocking these pathways it reduces fibroblast activity, extracellular matrix formation, and abnormal blood vessel growth, which together help slow fibrosis and limit tumor vascularisation.

The exact dose of Ofev is determined by the prescribing clinician based on the approved indication, patient weight, renal function and tolerability. Available strengths are 100 mg and 150 mg hard gelatin capsules, and the prescriber selects the appropriate regimen for each individual.

Ofev is classified as pregnancy category D, indicating evidence of risk to the fetus. It is not recommended for use during pregnancy unless the potential benefit justifies the risk. Breastfeeding is also discouraged because the drug may pass into milk; patients should discuss alternatives with their healthcare provider.

To order Ofev, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both Ofev (nintedanib) and pirfenidone are approved for idiopathic pulmonary fibrosis, but they have different mechanisms; Ofev targets multiple tyrosine kinases, while pirfenidone has anti‑inflammatory and antifibrotic actions. Clinical choice often depends on patient tolerance, drug‑drug interaction profile, and physician experience.

Ofev capsules should be stored at ambient temperature below 25 °C, in their original blister pack, protected from moisture and direct sunlight. Do not refrigerate or freeze the product, and keep it out of reach of children.

Ofev is taken orally as a hard gelatin capsule, usually with food to lessen gastrointestinal upset. The capsule should be swallowed whole with water and not crushed, chewed, or opened. Dosing timing and frequency are set by the prescribing clinician.

Serious risks include elevated liver enzymes indicating hepatic injury, bleeding complications such as gastrointestinal hemorrhage, and severe infections. Patients should report any signs of jaundice, unusual bruising, blood in stool or vomit, and persistent fever to their healthcare professional promptly.

Ofev should be avoided in patients with severe hepatic impairment, active bleeding disorders, uncontrolled hypertension, or those receiving strong CYP3A4 inducers that markedly reduce drug exposure. Contra‑indications also include known hypersensitivity to nintedanib or any capsule excipients.